Beneficial effects of combination therapy with losartan and low-dose hydrochlorothiazide in the treatment of essential hypertension

Japanese Journal of Nephrology

Volumn 47, Issue 8, 2005, Pages 864-869

  Minami, Junichi ^a   Ishimitsu, Toshihiko ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Combination therapy; Hydrochlorothiazide; Hypertension; Losartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIURETIC AGENT; GLUCOSE; HYDROCHLOROTHIAZIDE; LIPID; LOSARTAN; URIC ACID;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; PULSE RATE; PULSE WAVE;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BLOOD PRESSURE; DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; TETRAZOLES;

EID: 30044451026     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
2. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
3. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.
4. J-HOME (J-HOME). Ther Res 2003; 24: 1849-4855.
5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diureteic. The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2003; 288: 2891-2997.
6. Turner RC, Holman RR, Matthews D, Hockaday TD, Peto J. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 1979; 28: 1086-1096.
7. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beever G, Faire UD, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pederse O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
8. Dahlöf B, Devereux RB, Kjeldsen SE. Diuretics in the LIFE study. Lancet 2004; 364: 413-414.
9. Conlin PR, Spence DJ, Williams B, Ribeiro AB, Saito I, Benedict C, Bunt AMG. Angiotensin II antagonists for hypertension: Are there differences in efficacy? Am J Hypertens 2000; 13: 418-426.
10. Goldberg AI, Dunlay MC, Sweet CS. Safety and Tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-795.
11. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427-1431.
12. Christpher M, Dezii RN. A Retrospective Study of Persistence with Single-Pill Combination Therapy Vs. Concurrent Two-Pill Therapy in Patients with Hypertension. Manag Care 2000; 9(Suppl): S2-S6.
13. Muller JE, Stoone PH, Turi ZG, Rutherford JD, Czeisler, Parker C, Poole WK, Passamani E, Roberts R, Robertson T, and et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313: 1315-1322.
14. Muller JE, Ludmer PL, Willich SN, Tofler GH, Klangos AI, Stone PH. Circadian variation in the frequency of sudden cardiac death. Circulation 1987; 75: 131-138
15. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood pressure. Lancet 1978; 1: 795-797.
16. Willich SN, Levy D, Rocco MB, Tofler GH, Stone PH, Muller JE. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study Population. Am J Cardiol 1987; 60: 801-806.
17. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401-1406.
18. Pickering TG, Levenstein M, Walmsley P. Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group. Am J Hypertens 1994; 7: 844-847.
19. Ishimitsu T, Minami J, Kawano Y, Numabe A, Takishita S, Matsuoka H. Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients. Clin Exp Pharmacol Physiol 1999; 26: 500-504.
20. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996; 49: 1787-1790.
21. Enomoto A, Kimura H, Chairoungdus A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichikawa K, Hosoya T, Shimokawa K, Niwa T, Kanai Y, Endou H. Molecular indentification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-452.